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Abstract
Objective—Increased levels of Type I interferon (IFN-I) and IFN-I-regulated genes are found in 
patients with systemic lupus erythematosus (SLE) and may be central to its pathogenesis. The 
mitochondrial adaptor protein MAVS is a key regulator of IFN-I that undergoes a dramatic prion-
like aggregation and self-propagates the activation signal from viral RNA to amplify downstream 
IFN production. We wondered if such MAVS aggregates might play a role in the sustained 
increased production of IFN-I in SLE.
Methods—Peripheral blood mononuclear cells (PBMCs) were isolated and mitochondrial 
extracts were prepared. MAVS aggregation was detected with semi-denatured agarose gel 
electrophoresis (SDD-AGE) and confirmed by immunofluorescence staining. MAVS-associated 
signaling proteins were analyzed by Western blot. MAVS aggregation-associated gene expression 
signature was analyzed by microarray.
Results—Blood cells from 22 of 67 SLE patients were found to have essentially all of their 
MAVS in a high molecular weight aggregated form. None of six rheumatoid arthritis patients and 
only three of 33 healthy controls had abnormal MAVS. The MAVS-aggregate positive SLE 
patients had significantly higher serum levels of IFN-β and significantly increased auto-antibodies 
against Sm and U1RNP, compared to MAVS-aggregate negative patients. Gene array data revealed 
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a characteristic gene expression pattern in these patients, with altered expression of genes involved 
in IFN signaling and membrane trafficking.
Conclusion—Persistent MAVS aggregates may lead to increased IFN-I production and result in 
unmitigated signals leading to autoimmunity.
Patients with systemic lupus erythematosus (SLE) have elevated type I interferon (IFN-I) 
and IFN-inducible gene expression, the “IFN signature”, implicated in disease etiology and 
activity. Type I interferon production is regulated to a considerable extent by Toll-like 
receptor signaling, and abnormalities in this pathway have been described in lupus patients 
(1, 2). The more recently described RIG-I signaling pathway also plays an important role in 
IFN-I production. The mitochondrial antiviral signaling protein MAVS is required for this 
pathway of innate anti-viral defense (3–6). RIG-I/MDA5 recognizes viral dsRNA and 
undergoes a conformational change to induce the activation of MAVS, ultimately engaging 
nuclear factor κ-B (NFκ-B) and IRF3/7 activation through TRAF6/3, respectively (7). 
Coordinated activation of these transcription factors triggers inflammatory cytokine and 
IFN-I production. Supporting the notion that RIG-I signaling is important in respond to viral 
infection in vivo. MAVS deficient mice are severely compromised in anti-viral defense (8).
The RIG-I pathway may contribute to increased IFN inducible gene activation in SLE, 
resulting in increased disease activity. Transient exposure to a RIG-I ligand aggravates 
murine lupus nephritis via IFN signaling (9). Polymorphisms in Ifih1 (IFN-induced helicase 
1 gene, encoding MDA5) are associated with susceptibility to autoimmune diseases. 
Constitutively activated MDA5 (Gly821Ser) leads to a murine SLE-like phenotype, with 
increased IFN-I and IL-6, lymphocyte infiltration, complement deposition, and nephritis. 
The SLE-like disease requires functional MAVS (10). Overexpression of MAVS in fish cells 
causes constitutive induction of IFN and IFN-stimulated genes (ISGs) (11). Polymorphisms 
of human MAVS are associated with SLE susceptibility and manifestations (12). A loss-of-
function variant (C79F) of MAVS is associated with low levels of IFN-I in SLE patients, 
together with absence of RNA-protein binding autoantibodies (13).
Recently, Hou et al discovered that MAVS forms remarkable prion-like aggregates that 
propagate RIG-I signaling (14). Aggregated MAVS is detergent- and protease-resistant, and 
mediates signal transduction by autocatalytic conformational conversion of the adapter. We 
wondered if inappropriate or persistent MAVS aggregation might lead to increased IFN-I 
production, immune stimulation, and systemic autoimmunity in SLE. Our findings indicate 
that in a significant fraction of SLE patients, there is MAVS aggregation in peripheral blood 
cells, raising the possibility that this abnormality reflects persistent MAVS signaling and 
underlies type I interferon production, contributing to the development of SLE.
PATIENTS AND METHODS
Study populations
Patients were from the Lupus Clinic at Temple University Hospital. The studies were 
approved by the Temple University Institutional Review Board. After informed consent was 
given, we obtained blood from patients who satisfied diagnostic criteria of the ACR 
(American College of Rheumatology) for SLE and RA. Disease activity was assessed by the 
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SLEDAI activity index and determined on the day of blood draw. 67 SLE patients (64 
females and 3 males), 6 RA patients and 33 normal age-, sex-, and race-matched controls 
were enrolled in the study 2012–2014. Of these, 22 were Hispanic, 38 African-American, 1 
Asian, and 5 Caucasian.
Serology
Anti-nuclear antibodies, anti-dsDNA, anti-Sm, anti-RNP, anti-cardiolipin antibodies, serum 
C3 and C4, and antibodies to SS-A and SS-B were measured in our clinical laboratories and 
also at RDL Laboratories (Santa Monica, CA) using standard clinical protocols.
PBMC preparation and MAVS aggregation detection
Peripheral blood mononuclear cells (PBMCs) were prepared using Ficoll/Hypaque 
sedimentation. Crude mitochondria and cytosolic extracts were obtained through differential 
centrifugation as described (14). Briefly, we added buffer A (10 mM Tris-HCl, pH 7.5, 10 
mM KCl, 1.5 mM MgCl2, 0.25 M D-mannitol, and Pierrs EDTA-free protease inhibitor 
cocktail) into 3 × 106 PBMCs and then lysed by repeated douncing. Cell debris was removed 
by centrifugation (1000 × g, 5 min) and the supernatants were then centrifuged again at 
10,000 × g for 10 min at 4°C to obtain the supernatant (cytosolic extracts, S5) from the 
pellet (mitochondria enriched samples, P5). MAVS aggregation was detected with SDS-
AGE according to previous publications (14). In brief, P5 and S5 were suspended in 1× 
sample buffer (0.5 × TBE, 10% glycerol, 2% SDS, and 0.0025% bromophenol blue) and 
loaded onto a vertical 1.5% agarose gel. We then ran electrophoresis in 1 × TBE buffer 
supplied with 0.1% SDS and transferred to Immobilon membranes for immunoblotting.
Microscopy
PBMCs from lupus patients and normal controls were incubated with 200 nM of 
MitoTracker Red (Life Technologies) in pre-warmed RPMI-1640 for 45 minutes in the dark. 
Cells were then washed, fixed, and permeabilized with BD Cytoperm buffer. Rabbit anti-
MAVS antibody was diluted into the Per/Wash buffer and incubated for 20 minutes with 
cells. FITC-conjugated anti-rabbit secondary antibody was added after washing. Images 
were captured with a Zeiss confocal microscope (LSM 510META, Germany).
IFN-β analysis
IFN-β was detected using the human IFN-β ELISA kit (Fujirebio Inc. Tokyo, Japan) 
following the manufacture’s procedure. In brief, the antibody-coated microplate was washed 
and incubated with serum and enzyme-linked secondary antibody for 2 hours at room 
temperature. Color developer was then added into each well after 3 washes. The reaction 
was stopped after 30 minutes. Absorbance was read at 450nm with a reference at 620nm.
Gene expression analysis
Total RNA was extracted from all SLE and control PBMCs and the cRNA was run on HT-
HG-U133-plus (Affymetrix) oligonucleotide microarrays containing ~47,000 human 
transcripts (15). RMA function was applied to correct for background and to normalize the 
raw expression values. A linear model to the data was fitted in order to identify 
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Differentially Expressed (DE) genes (16). A Support Vector Machine (SVM) with Recursive 
Feature Selection was applied to determine which genes divided MAVS aggregates positive 
from negative samples. The top 30 genes were selected from the SVM analysis and 
clustering analysis was performed using Pearson correlation.
Western blotting
Western blot analysis was performed using standard procedures. Antibodies against MAVS 
(1:1000, Santa Cruz), IRF3, pho-IRF3 (1:1000, Abcam), NLRC3, NLRX1 (1:2000, Ting 
Lab (17)), TRAF3 (1:200, Santa Cruz), TRAF6, Stat1 (1:500, Santa Cruz), PCBP2 and 
ARCH5 (1:500, Abcam), gC1qR (1:1000, Santa Cruz), β-actin (1:200,000, Abcam) were 
used.
Statistics
Western blot data were analyzed using the ImageStudio software (Li-Cor, Lincoln, NE). 
Intensity differences between groups were tested using the Mann-Whitney U test. A p value 
of less than 0.05 was considered to be significant. Data are shown as median with 
interquartile range. Chi square with Yates correction was used to compare prevalence of 
autoantibodies between groups.
RESULTS
MAVS aggregates in the PBMCs of SLE patients
SLE patients fulfilled American College of Rheumatology (ACR) criteria. We analyzed 
MAVS aggregation status in PBMCs of 67 SLE patients and 33 controls. Mitochondria-
enriched P5 samples were lysed and separated by vertical semi-denaturing agarose gel 
electrophoresis (SDD-AGE) to detect prion particles (Figure 1) (14). To our initial surprise, 
over a third of patients with SLE showed aggregation of the MAVS protein when analyzed 
using the SDD-AGE method. The aggregation was usually marked, with most of the MAVS 
protein present in aggregate form. To judge whether individual samples were aggregate-
positive or negative, we arbitrarily considered a ratio of ≥10 for relative intensity (compared 
to β-actin protein levels) as positive aggregation (Figure 1). To confirm our initial 
observation, we measured the protein levels of MAVS with conventional, fully denatured 
SDS-PAGE and compared MAVS levels to those of the housekeeping gene β-actin. We 
found no correlation between the total levels of MAVS protein and the presence of MAVS 
aggregation (Figure 1B and C). We also detected MAVS aggregation using multiple anti-
MAVS antibodies from different sources and obtained consistent results (Figure 1B and C). 
Cells from 32.8% (22 out of 67) SLE patients had a prion-like high molecular weight form 
of MAVS, compared to 9% (3 out of 33) of normal controls (Figure 1A, B, C, and data not 
shown). None of PBMC from six RA patients meeting ACR/EULAR criteria showed the 
high-molecular weight smear indicating MAVS aggregation (Figure 1D).
We had the opportunity to examine additional samples from nine SLE patients over the 
course of about a year to address the question of whether MAVS aggregation was a stable 
characteristic or if it changed over time. For three MAVS aggregation positive patients, only 
one remained positive when assayed a second time. Four MAVS aggregation negative 
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patients remained negative when sampled a second time, and two negative patients showed 
MAVS aggregation when examined at a later time. Thus, MAVS aggregation is not a stable 
phenotype for lupus patients, but changes over time.
To visualize MAVS aggregation in cells, we stained PBMCs with MitoTracker-PE, rabbit 
anti-MAVS, and then Alexa-488 anti-rabbit IgG. Confocal fluorescence microscopy revealed 
that Alexa-MAVS formed clusters that partially overlapped with MitoTracker from MAVS-
aggregates positive PBMCs detected by SDD-AGE, but not from MAVS-aggregates negative 
samples. Mitochondria from MAVS aggregates positive PBMCs tended to cluster together, 
suggesting a role of mitochondrial membrane association (Figure 1E). In Sendai virus-
infected fibroblasts, disulfide bonds were required for the aggregated form of MAVS (14). 
We found that incubation with β-mercaptoethanol reduced the high-molecular weight MAVS 
aggregates to the low-molecular weight range (Figure 1F), confirming this requirement for 
SLE patients.
MAVS aggregates are associated with down-regulation of the MAVS-regulatory protein 
C1qr and MARCH5, yet levels of NLRC3 and NLRX1 are the same in aggregates-positive 
and aggregates-negative individuals
We asked whether MAVS aggregates might reflect lack of a down-regulatory effect of 
known inhibitors of this protein. MAVS regulating proteins in the cytoplasmic preparation 
(S5) and mitochondria portions (P5) were analyzed by Western blot and the levels of several 
proteins known to affect MAVS were examined. We found that cytoplasmic C1qr, a negative 
regulator of MAVS signaling (18), was significantly reduced in the PBMCs of SLE patients 
with aggregated MAVS, compared to MAVS aggregation-negative SLE patients and normal 
controls (Figure 2A). Down-regulation of C1qr may be one of the mechanisms leading to 
impaired inactivation of MAVS in some SLE patients. MARCH5 and PCBP2 (poly(rC) 
binding protein 2) are recently identified MAVS-linked proteins (19, 20). Association of 
MAVS with either MARCH5 or PCBP2 promotes proteasome-mediated degradation of 
MAVS. Western results revealed a significant decrease of MARCH5 in MAVS aggregation 
positive SLE patients compared to the MAVS aggregation negative SLE patients (Figure 3). 
It is of note that MARCH5 only binds MAVS when it forms aggregates (20). Cytoplasmic 
Stat1 levels were also significantly low in MAVS aggregation positive SLE patients, 
compared to both normal controls and SLE patients without MAVS aggregation (Figure 2A). 
Stat1 activation was associated with translocation into the nucleus (21). Decreased 
cytoplasmic levels of Stat1 in MAVS aggregation positive SLE patients may reflect its 
activation and translocation into nucleus. There was no difference in Stat1 levels in the P5 
samples (Figure 2B).
MAVS activation recruits adaptor proteins (TRAF3 and TRAF6) that activate transcription 
factors. Induction of the NF-κB pathway occurs via the recruitment of TRAF6 (22). Western 
blot results revealed no difference in protein levels of TRAF6 between normal controls and 
SLE patients, but TRAF6 levels were low in the PBMCs of SLE patients with aggregated 
MAVS (Fig. 2A), a trend only observed for the cytoplasmic preparations (S5) but not the 
mitochondria samples (P5). In contrast, TRAF3 levels were significantly higher in the 
mitochondria preparations (P5) from MAVS aggregation positive SLE patients compared to 
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normal controls (Figure 2B). MAVS interacts with TRAF3, which leads to the subsequent 
phosphorylation of IRF3. IRF3 dimers translocate to the nucleus and bind the interferon 
stimulated response elements (ISRE) (22). We noted an increased level of IRF3 in PBMCs 
from SLE patients compared to normal controls, indicating active IFN signaling in SLE 
patients (Figure S1A). However, the activated form of IRF3 (Ser396 phosphorylated IRF3, 
p-IRF3) was no different in SLE patients with or without MAVS aggregation (Figure S1A).
NLRC3 plays inhibitory roles during inflammation. It may interact with the RIG-I-MAVS 
pathway via stimulator of interferon genes (STING) (23). Enhanced NF-κB activation was 
observed in nlrc3−/− macrophages. NLRC3 can also regulate TRAF6 activation by 
modulating its K63-linked ubiquitination (23). K63 ubiquitin chains bind and activate RIG-I 
(3). Furthermore, MAVS aggregation leads to recruitment of TRAF6, promoting an 
inflammatory response. We analyzed protein levels of NLRC3 by Western blot. A slightly 
increased level of NLRC3 seemed to associate with aggregated MAVS, but the difference 
did not achieve statistical significance (Figure S1B). Further experiments will be needed to 
define whether NLRC3 regulates MAVS aggregation/activation. NLRX1 is another negative 
regulator of IFN-I (17) and inhibits the interaction between MAVS and RIG-I. NLRX1 did 
not seem to be involved in MAVS aggregation, as there was no difference in protein levels of 
NLRX1 between MAVS aggregate positive and negative SLE patients (Figure S1B). 
Surprisingly, we found expression of NLRX1 in cytoplasmic preparations from SLE patients 
(Figure S1B), although the majority of the protein does reside in the mitochondria. However, 
previous work was performed in mouse cells and not PBMC, thus this finding will need to 
be followed up with a more complete survey of expression in patients and in normals.
MAVS aggregates are associated with increased circulating IFN-I
Next, we examined the clinical significance of MAVS aggregates in SLE. We postulated that 
persistent MAVS aggregates might upregulate type I IFN production in SLE patients and 
consequently influence disease pathogenesis and clinical phenotype. To evaluate levels of 
IFN-I in the lupus cohort with positive MAVS aggregates, we first aligned our RNA-seq data 
to the human genome hg19 (24). Patients were clustered based on the expression of 27 
interferon signature genes (25). Three major clusters were detected: high, moderate/medium, 
and low interferon signature. Frequency of MAVS aggregation positive patients was higher 
in the high interferon signature cluster (60% (6/10) of Agg+ in the high signature cluster 
compared to 30% (6/20) of Agg- in the same signature cluster) (Figure 4A). We then 
measured the IFN-β levels in plasma samples collected along with the PBMCs. We found 
significantly elevated IFN-β levels in MAVS Agg+ patients compared to both the Agg- SLE 
patients and the normal controls (Figure 4B). Taken together, MAVS aggregates showed a 
correlation with type I IFN responses in SLE.
A characteristic gene expression pattern in MAVS aggregates positive SLE patients
To identify a possible gene expression signature unique to MAVS aggregates positive SLE 
patients, we analyzed PBMCs from 27 MAVS SLE patients and 21 age, ethnicity, and sex-
matched controls. We performed clustering analysis using the RNA-seq data. Patients with 
PBMC MAVS aggregation clustered together, suggesting that MAVS aggregation led to a 
specific differential gene expression pattern. 20 genes were up-regulated and 10 genes were 
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down-regulated in MAVS Agg+ SLE patients, compared with MAVS Agg- SLE patients 
(Figure 5). The most commonly up-regulated transcripts corresponded to DNA/protein 
binding and organelle trafficking (Sdcbp2, Klc4, Kncn, and Cnnm3). Pias2, a member of the 
protein inhibitor of activated STATs (PIAS) family, was down-regulated. Pias2 encodes a 
transcriptional co-regulator in the STAT pathway and p53 pathway, both playing roles in 
SLE pathogenesis. Notably, three genes (Fkbp1a, Gimap1, and Sox4) classified by gene 
ontology analysis are involved in T-cell activation, lymphocyte activation and leukocyte 
activation.
Disease Phenotype in MAVS-aggregate positive vs. negative SLE patients
We looked at disease activity and at the spectrum of organ involvement in patients with and 
without MAVS-aggregation. We compared demographics, drug therapy, and clinical features 
of disease between the two groups and found no significant differences, nor were there 
differences in SLEDAI (not shown) between groups. We analyzed serological data from 
MAVS aggregates-positive SLE patients and compared them to the MAVS aggregates 
negative SLE patients. Data are shown in Table I. All SLE patients were positive for anti-
nuclear antibodies (ANA). Autoantibodies are recorded as positive or negative as recorded in 
the medical record (Table I). Using this measure, patients with MAVS aggregation were 
significantly more likely to have had antibodies to U1RNP and Sm. They were significantly 
less likely to have antibodies to cardiolipin. All of the stored plasma samples (from blood 
samples taken at the time MAVS aggregation was assessed) were subsequently re-analyzed 
by a commercial laboratory (RDL, Santa Monica, CA). As seen in Table I bottom, when this 
cohort of samples was analyzed, there were no significant differences in the prevalence of 
the panel of autoantibodies when aggregate positive patients were compared to aggregate-
negative patients.
DISCUSSION
The connection between infections and autoimmunity has been known for decades. 
Microbial invasion is detected by cellular sensors and initiates immune responses through 
cytokine production. Cytosolic RIG-I-like helicases (RIG-I and MDA5) specifically bind 
viral RNAs and trigger a robust antiviral response through MAVS (26). Active MAVS 
undergoes significant biochemical changes, leading to its aggregation into large prion-like 
fibers, resistant to detergents and proteinases (22). Prion-like MAVS catalyzes further 
polymerization of native MAVS proteins, mediating downstream signaling and IFN 
production (27). Structural and biophysical analyses of MAVS indicate its respective prion 
conversion involves an all-or-none transition from monomers to polymers (10, 28, 29). 
Indeed, all MAVS aggregates in our study are essentially in the high-molecular form. The 
initial activation of the RIG-I pathway in SLE may be provoked by viral infection. The 
persistence of MAVS aggregates may reflect a decreased ability to degrade poorly soluble 
prion-like aggregates resulting from RIG-I signaling. Degradation of MAVS aggregates 
occurs by several mechanisms and may be required to shut down the IFN antiviral response. 
Delayed or impaired clearance of aggregated MAVS may represent a disease mechanism 
leading to increased steady-state IFN-I pathway activation.
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MAVS aggregation was found in over a third of patients with SLE. Data regarding disease 
phenotype in MAVS-aggregate positive versus MAVS-aggregate negative patients were 
inconclusive. There was no apparent difference between aggregate positive and negative 
patients in disease manifestations, nor in disease activity as measured by SLEDAI. Clinical 
laboratory testing suggested an increased prevalence of anti-Sm and U1RNP antibodies; yet 
this was not seen when patient samples obtained at a different time were analyzed as a 
cohort. There was a trend toward statistical significance of the anti-Sm and U1RNP findings. 
Methodological differences between the two sets of autoantibody assays may explain results, 
as well as the fact that they were from samples taken at different times. Further study of the 
clinical significance of MAVS aggregation is needed.
It is of note that a few apparently normal individuals had evidence of MAVS aggregation. 
These people might be responding abnormally to common minor viral illnesses or might 
have constitutive MAVS aggregation that might predispose them to autoimmune disease. 
Further study of MAVS aggregation in these normal individuals might reveal an increased 
tendency to develop autoimmune disease.
Mutations in RIG-I like receptors may also provoke IFN-I secretion. The RLRs are usually 
expressed at very low levels. The sensitive and robust switch of MAVS to its prion state 
perpetuates downstream MDA5-mediated antiviral signaling (27). The constitutively 
activated form of MDA5 exerts a strong phenotype of autoimmunity in mice without viral 
infection. The autoimmune phenotype is MAVS and IFN-I dependent, as deficiencies of 
IFN-I receptor and MAVS abrogated the lupus-like clinical manifestations, respectively (10). 
Remarkably, human alleles of the same MDA5 mutation exhibited similar downstream 
effects, including constitutive IFN production. In MRL/lpr mice, exposure to 5′-triphosphate 
RNA aggravates autoimmunity and lupus nephritis (9). MAVS aggregates observed in our 
lupus patients may be triggered by the upstream RLRs.
Our patients showed a characteristic pattern of gene activation by microarray analysis of 
47,000 genes. Principal Component Analysis revealed altered expression of genes involved 
in protein-protein interaction, vesicular trafficking, E3 ligase binding, and Stats inhibition. 
KLHL23 is an E3 ligase binding protein. E3 ligase mediated MAVS degradation is an 
important mechanism in regulating MAVS aggregates. Increased KLHL23 in MAVS 
aggregates patients may suggest a compromised mechanism toward the impaired 
degradation of MAVS polymer. The ability of mitochondria to fuse properly and maintain an 
adequate membrane potential is crucial for MAVS signaling. Of 20 genes showing enhanced 
expression, five (Cyth4, Cyp4b1, Hoxc9, Kncn, and Klc4) mediate the regulation of protein 
sorting and membrane trafficking. Interestingly, expression of Pias2 (encoding a member of 
the protein inhibitor of activated Stat) was down regulated in MAVS aggregates positive 
patients. PIAS2 has a critical role as a transcriptional regulator of Stat-signaling (30). C1qr 
was significantly low in the MAVS aggregation positive SLE patients, compared to normal 
controls and MAVS aggregation negative SLE patients. Since C1qr plays an inhibitory role 
in MAVS activation/aggregation, lower C1qr may indicate a defect in controlling MAVS 
aggregation. We are particularly interested in the significantly decreased protein levels of 
MARCH5 in MAVS aggregation positive SLE patients as MARCH5 only binds to the 
aggregated form of MAVS (20). This decreased MARCH5 protein may account for the 
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persistent MAVS aggregation in our SLE patients. However, this abnormality deserves 
further study. Finally, it would also be important to analyze the signaling proteins with total 
protein extracts instead of cytosol and mitochondria fraction. Western blot with nuclear 
extractions may reveal the importance of IRF3 activation in the SLE Agg+ PBMCs.
Our finding of the aggregated form of MAVS in the PBMCs of SLE patients provides a 
potential mechanism linking innate immunity in the development of autoimmune disease, 
and may explain the elevated type I interferon levels in SLE.
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Figure 1. MAVS aggregation in SLE patients
A. MAVS aggregation was assessed by SDD-AGE (“c”. Jurkat T cell control; “+”. 
Aggregate positive; “−”, Aggregate negative). B and C, MAVS aggregation was detected and 
confirmed both in SDD-AGE and SDS-PAGE gel with antibodies from Abcam (B) and 
Santa Cruz (C). β-actin was used to indicate the total protein loading. D. Visualization of 
MAVS aggregates from lupus patients. Normal control (left), aggregate-negative patient 
(SB11 shown in SDD-AGE, right panel), and aggregate-positive lupus patient (arrows, SB17 
shown in SDD-AGE, right panel). MAVS aggregation were shown in yellow clusters (merge 
of MAVS-FITC and MitoTracker-Red) under confocal microscope. E. PBMC samples from 
lupus patients (let) and RA patients (right) were analyzed by SDD-AGE. F. 2 MAVS 
aggregate positive samples were treated with β-mercaptoethanol and analyzed by SDS-AGE 
in parallel. Data are representative of 67 SLE patients and 33 controls.
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Figure 2. Levels of protein involved in MAVS signaling
MAVS associated proteins in the cytoplasm samples (S5, A) and mitochondria samples (P5, 
B) were analyzed by Western blot. Representative Western images are shown (MAVS 
aggregates positive samples were indicated with ‘★’). Densitometry analysis to quantify 
ratio of indicated protein to b-actin is shown at the bottom. Values are expressed as median 
with interquartile range. Statistical test is the Mann-Whitney test, * p<0.05.
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Figure 3. Decreased MARCH5 is associated with MAVS aggregation
MAVS negative regulators PCBP2 and MARCH5 were analyzed by Western blot in the 
cytoplasm samples (S5) and mitochondria samples (P5). Representative Western images are 
shown (MAVS aggregates positive samples were indicated with ‘★’). Densitometry analysis 
to quantify ratio of indicated protein to β-actin is shown at the bottom. Values are expressed 
as median with interquartile range. Statistical test is the Mann-Whitney test, * p<0.05.
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Figure 4. Increased IFN-I signature in MAVS Agg+ SLE patients
A. RNA-seq data (100-bp paired-end reads) were aligned to the human genome hg19 using 
TopHat (24). Libraries normalization was performed and FPKM for each RefSeq gene was 
calculated using Edger, a package in R (31). 27 interferon related genes, used by ARGOS in 
their clinical trial were used to cluster patients based on expression of this interferon 
signature (25). B. IFN-β levels in the plasma samples of SLE patients and normal controls 
were measured using a human IFN-β ELISA kit (Fujirebio Inc. Tokyo, Japan). Results were 
expressed as individual data points with means ±SEM. Statistical test is the unpaired t test, * 
p<0.05.
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Figure 5. Signature gene expression pattern in MAVS aggregation positive patients
Microarray was run on Affymetrix HT-HG-U133-plus (15). A Support Vector Machine 
(SVM) with Recursive Feature Selection was applied to determine which genes divided 
MAVS Agg+ from Agg- samples. The top 30 genes were selected from the SVM analysis 
and clustering analysis was performed using Pearson correlation.
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